Big effect
A meta-analysis of 54 trials found microbiome-targeted therapies cut 2-hour post-meal blood sugar by 43 mg/dL — but the effect came from a mix of interventions, not just one supplement, and long-term data is missing.
This is the first big-picture look at Bifidobacterium lactis Bb-02 and similar therapies for type 2 diabetes, so the result is promising but still preliminary — we don't yet know if the effect lasts or applies to everyone.
In a large analysis of 54 randomized trials, therapies that target the gut microbiome — including the probiotic Bifidobacterium lactis Bb-02 — modestly lowered fasting blood sugar, after-meal blood sugar, and a long-term glucose marker called HbA1c in people with type 2 diabetes. The studies also showed drops in inflammation and increases in beneficial gut bacteria, but the results varied a lot between trials, and none tracked people long enough to know if the benefits hold up over years.
Where this fits in the evidence
This is among the first studies we've indexed on Bifidobacterium lactis Bb-02 for Improved Glycemic Control — treat it as an early signal until more research accumulates.
The study
- Meta-Analysis
- n = 3,390
- 2025-06-09
- The Journal of clinical endocrinology and metabolism
- PubMed: 40489582
- DOI: 10.1210/clinem/dgaf340
- Full study breakdown →
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.